Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials?

Toxicologic Pathology

Volumn 33, Issue 1, 2005, Pages 146-154

  Peters, Terry S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

drug development; Hepatotoxicity; preclinical testing

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BROMFENAC; CARBON TETRACHLORIDE; CLARITHROMYCIN; COCAINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCOSE; ISONIAZID; PARACETAMOL; TELITHROMYCIN; TROGLITAZONE; TROVAFLOXACIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY EXCRETION; BIOACCUMULATION; CHOLESTASIS; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; GENETIC REGULATION; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNE MEDIATED INJURY; LABORATORY TEST; LIVER CARCINOGENESIS; LIVER CELL DAMAGE; LIVER FAILURE; LIVER FIBROSIS; LIVER MICROSOME METABOLISM; LIVER NECROSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; TOXIC HEPATITIS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; LIVER; PREDICTIVE VALUE OF TESTS; SPECIES SPECIFICITY; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; ORYCTOLAGUS CUNICULUS; PRIMATES; RODENTIA;

EID: 13444302921     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230590522121     Document Type: Article

References (42)

1. Alden C, et al Predictive toxicology technology for avoiding idiosyncratic liver injury Preclinica 2003 May/June 27 35
2. Benichou C Criteria of drug-induced hepatic disorders. Report of an international consensus meeting J Hepatol 1990 11 272-6
3. Boelsterli UA Idiosyncratic drug hepatotoxicity revisited Toxicol Mech Meth 2003a 13 1 3 20
4. Boelsterli UA Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity Curr Opin Drug Disc Deliv 2003b 6 1 81 91
5. Chitturi S, George J Hepatotoxicity of commonly used drugs Semi Liver Dis 2002a 22 169-84
6. Chitturi S, George J Berk PD Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs Hepatotoxicity in the Twenty-First Century 2002b 22 169-84
7. Cohen SD, Hoivik DJ, Khairallah EA Plaa GL, Hewitt WR Acetaminophen-induced hepatotoxicity Toxicology of the Liver 1998 159-86
8. Cunha BA Antibiotic side effects Med Clin N Am 2001 85 1 149-85
9. Eaton DL, Klaassen CD Principles of toxicology Casarett and Doull's Toxicology: The Basic Science of Poisons 1996 5 NY, NY McGraw-Hill 13 33
10. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, Rabkin JM, Lee WM, The Acute Liver Failure Study Group Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation Liver Transplant Surg 1999 5 6 480-4
11. Goodman ZD Drug hepatotoxicity Clinic Liver Dise 2002 6 2 381-97
12. Greaves P, Williams A, Eve M First dose of potential new medicines to humans: how animals help Nature 2004 March 3 226-36
13. Gurumuthy P, Krishnamurthy MS, Nazareth O Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis Am Rev Respir Dis 1984 129 58 61
14. Kaplowitz N Drug-induced liver disorders: implications for drug development and regulation Drug Safety 2001 2001 24 7 483-90
15. Karthikeyan S Isoniazid induced hepatic steatosis—An acute toxicity study in rabbits Biomedicine 2002 22 3-4 69 78
16. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA Studies on the metabolism of troglitazone to reactive intermediates in vitro and In vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission Chem Res Toxicol 2001 14 1 62 70
17. Kennedy EL, Tchao R, Harvison PJ Nephrotoxic and hepatotoxic potential of imidazolidinedion-, oxazolidinedione- and thiazolidinedion-containing analogues of N-(3,5-dichlorophenyl) cuccinimide (NDPS) in Fischer 344 rats Toxicology 2003 186 79 91
18. Kleiner DE, Gaffey MJ, Sallie R, Tsokos M, Nichols L, McKenzie R, Straus SE, Hoofnagle JH Histopathologic changes associated with fialuridine hepatotoxicity Mod Path 1997 10 3 192-9
19. Lawson DH Adverse drug reactions Human Toxicol 1985 4 122-6
20. Lee WM Acute liver failure in the United States Sem Liver Dis 2003 23 3 217-26
21. Li AP A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity Chem Biol Interact 2002 142 1-2 7 23
22. Lin YL, Chern HD, Chu ML Hepatotoxicity in the review of clinical safety data Drug Info J 2002 37 155-8
23. Marra F, Efsen E, Romanelli RG, Caligivri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P Ligands of peroxisome proliferator-activated receptor gamma modulate profibrinogenic and proinflammatory actions in hepatic stellate cells Gas-troenterology 2000 119 2 466-78
24. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W Concordance of the toxicity of pharmaceuticals in humans and animals Regul Toxicol Pharmacol 2000 32 56 67
25. Ostapowicz G, et al Results from a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann Intern Med 2002 137 957-54
26. Park BK, Kitteringham NR, Powell H, Pirmohamed M Advances in molecular toxicology—towards understanding idiosyncratic drug toxicity Toxicology 2000 153 1-3 39 60
27. Roth RA, Luyendyk JP, Maddox JF, Ganey PE Inflammation and drug idiosyncrasy—Is there a connection? J Pharmacol Exp Ther 2003 307 1 1 8
28. Scheen AJ Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Safety 2001 2001a 24 12 873-88
29. Scheen AJ Thiazolidinediones and liver toxicity Diabetes Metab 2001b 27 3 305-13
30. Shain CS, Amsden GW Telithromycin: the first of the ketolides Ann Pharmacother 2002 36 452-64
31. Stumvoll M Thiazolidinediones—some recent developments Expert Opin Invest Drugs 2003 12 7 1179-87
32. Szela GA, Merwid LA, Trocha M, Skrzypiec M, Smereka A Pathomechanisms of drug hepatotoxicity Gastroenterologia Polska 2003 10 5 424-9
33. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richardson FC, Lewis W, Cote PJ, Korba BE, Geron JL Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection Hepatology 1998 28 179-91
34. Thiim M, Friedman LS Hepatotoxicity of antibiotics and anti-fungals Clin Liver Dis 2003a 7 2 381-99
35. Tolman KG Thiazolidinedione hepatotoxicity: a class effect? Int Jrnl of Clin Practice 2000 113 Suppl 29 34
36. Tsui WMS Drug-associated changes in the liver Curr Diagn Path 2003 9 2 96 104
37. Uetrecht JP Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr Drug Metab 2000 1 133-41
38. Wallace RJ, Brown BA, Griffith DE Drug intolerance to high-dose clarithromycin among elderly patients Diagn Microbiol Infect Dis 1993 16 215-21
39. Weber WW, Hein DW, Litwin A, Lower GM Jr Relationship of acetylator status to isoniazid toxicity, lupus erythematosis and bladder cancer Fed Proc 42 3086-91
40. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis Am J Respir Crit Care Med 2003 167 1472-7
41. Yew WW, Chau Chi Hung, Lee J, Leung Chin Wan Cholestatic hepatitis in a patient who received clarithromycin therapy Clin Infect Dis 1994 18 1025-6
42. Zimmerman HJ Drug-induced liver disease Clinics Liver Dis 2000 4 1 73 96